Motley Fool Premium
  1. Stocks
    2. /
  2. OXB (LSE: OXB)
    3. /

LSE:OXB (OXB)

About OXB

OXB is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

OXB (LSE: OXB) Latest News

Investing Articles

The Oxford Biomedica share price is up 80% in a year. Here’s what I’d do

| Alan Oscroft

The Oxford Biomedica (LON: OXB) share price has soared more than 600% in five years. Could there be be a…

Read more »

Investing Articles

The Oxford BioMedica share price surges on earnings

| Zaven Boyrazian, CFA

The Oxford BioMedica share price is on fire this month but can the upward momentum continue? Zaven Boyrazian explores its…

Read more »

Syringe and vial on blue background
Investing Articles

The Oxford Biomedica share price has doubled since signing its Covid-19 vaccine deal. Can the momentum continue?

| Megan Boxall

Oxford Biomedica’s share price is soaring. But is this simply the hype of its Covid-19 vaccine deal? Megan Boxall examines…

Read more »

Investing Articles

Top British stocks for July

| The Motley Fool Staff

We asked our freelance writers to share their top British stocks for July, including Smith & Nephew, Motorpoint and TI…

Read more »

Investing Articles

Will the Oxford Biomedica share price keep on climbing?

| Zaven Boyrazian, CFA

The Oxford Biomedica share price is surging after extending its deal with AstraZeneca. Zaven Boyrazian investigates if this momentum can…

Read more »

Investing Articles

Oxford Biomedica’s share price hits record peaks as it upgrades forecasts!

| Royston Wild

The Oxford Biomedica share price has roared to new all-time peaks as vaccine orders from AstraZeneca increase. Here are the…

Read more »

Investing Articles

Want to be a millionaire? I’d follow Warren Buffett’s example and buy cheap shares

| Zaven Boyrazian, CFA

Warren Buffett made his fortune in the stock market. Zaven Boyrazian explains how he did it, and how you can…

Read more »

Investing Articles

Top British stocks for January 2021

| The Motley Fool Staff

We asked our freelance writers to share their top British stocks for January, including Rio Tinto, Safestore and IG Group.

Read more »

Investing Articles

AstraZeneca’s Covid-19 vaccine approved! Here’s what I’d do now

| Zaven Boyrazian, CFA

Approval for AstraZeneca’s vaccine brings the UK a step closer to winning the fight against Covid-19. But is there a…

Read more »

Investing Articles

Covid-19 vaccine: 1 biotech stock that profits from AstraZeneca’s success

| Zaven Boyrazian, CFA

Another Covid-19 vaccine may soon be available from AstraZeneca. Zaven Boyrazian analyses the results and finds a larger opportunity for…

Read more »

Investing Articles

I’d buy these 2 growth stocks for explosive returns!

| Zaven Boyrazian, CFA

Looking for top UK shares to buy now? These two biotech growth stocks have been generating explosive returns for many…

Read more »

Investing Articles

Did Oxford Biomedica just find a new treatment for Parkinson’s disease?

| Zaven Boyrazian, CFA

Zaven Boyrazian takes another look at Oxford Biomedica after promising results on its Parkinson’s disease treatment were announced.

Read more »